Regeneron Pharmaceuticals Inc (WBO:REGN)
€ 757.4 -20.4 (-2.62%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 99/100

Regeneron Pharmaceuticals Inc at Guggenheim Biopharma's Next Decade Virtual Conference Transcript

Jun 29, 2021 / 02:00PM GMT
Release Date Price: €454.15 (-2.56%)
Yatin Suneja
Guggenheim Securities, LLC, Research Division - MD & Senior Biotechnology Analyst

Good morning, everybody, and welcome to Guggenheim Biopharma Strategy Series, Biopharma Next Decade: Views from the Top on Global Strategy and Innovation. Today, we have multiple members of the Regeneron management team, including George Yancopoulos, Chief Scientific Officer, Scientific Founder and the President; Brian Zambrowicz, SVP Functional Genomic and Chief Operation; Aris Baras, SVP, Regeneron Genetics Center; and Christos Kyratsous; VP, Research. We also have Justin Holko from the IR side on us.

The format of this session is going to be presentation by Regeneron followed by Q&A. For investors listening to the call, please feel free to e-mail me your questions at [email protected]. So with this opening remark, let me turn it over to Justin for a brief intro, and then we can go into the presentation. Justin?

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Yatin. And first things first, I'm going to try to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot